000266790 001__ 266790
000266790 005__ 20240808170924.0
000266790 0247_ $$2doi$$a10.1007/s00415-023-11985-8
000266790 0247_ $$2pmid$$apmid:37737892
000266790 0247_ $$2pmc$$apmc:PMC10769984
000266790 0247_ $$2ISSN$$a0367-004X
000266790 0247_ $$2ISSN$$a0012-1037
000266790 0247_ $$2ISSN$$a0340-5354
000266790 0247_ $$2ISSN$$a1432-1459
000266790 0247_ $$2altmetric$$aaltmetric:154529363
000266790 037__ $$aDZNE-2024-00048
000266790 041__ $$aEnglish
000266790 082__ $$a610
000266790 1001_ $$00009-0004-0187-5973$$aWiesenfarth, Maximilian$$b0
000266790 245__ $$aNeurological manifestation of HEV infection: still a rare disease entity?
000266790 260__ $$aHeidelberg$$bSpringer$$c2024
000266790 3367_ $$2DRIVER$$aarticle
000266790 3367_ $$2DataCite$$aOutput Types/Journal article
000266790 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705503606_18422
000266790 3367_ $$2BibTeX$$aARTICLE
000266790 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000266790 3367_ $$00$$2EndNote$$aJournal Article
000266790 520__ $$aHepatitis E virus (HEV) infection is the most common form of viral hepatitis and is reported to cause neurological manifestation in up to 30% of diagnosed infections. We evaluated the medical reports of all patients (n = 29,994) who were discharged from the Department of Neurology of Ulm University between 01.01.2015 and 30.09.2022 to detect neurological manifestations of HEV. In addition, we retrospectively analyzed the serum samples of n = 99 patients representing different neurological diseases possibly related to HEV for anti-HEV-IgM and anti-HEV-IgG. At the time of discharge from hospital, the etiology of neurological symptoms in these patients was unclear. Overall, five cases of extrahepatic neurological manifestation of HEV (defined as anti-HEV-IgM and HEV-IgG positive) could be detected. An increase of both, anti-IgM- and anti-IgG-serum levels was significantly more common in neuralgic amyotrophy/plexus neuritis/radiculitis than in AIDP/CIDP (P = 0.01), meningitis/encephalitis (P = 0.02), idiopathic peripheral facial paralysis (P = 0.02) and tension headache (P = 0.02). In 15% (n = 15 out of 99) of retrospectively analyzed serum samples, conspicuous positive anti-HEV-IgG levels were detected. This finding was most common in AIDP/CIDP. In conclusion, results of this study indicate neurological manifestation of HEV to be a rare but still underestimated course of disease, occurring at any age and gender. Therefore, testing for HEV should be considered in patients with neurological symptoms of unknown origin, especially in those with neuralgic amyotrophy/plexus neuritis.
000266790 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000266790 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000266790 650_2 $$2MeSH$$aHumans
000266790 650_2 $$2MeSH$$aHepatitis E virus
000266790 650_2 $$2MeSH$$aBrachial Plexus Neuritis: diagnosis
000266790 650_2 $$2MeSH$$aBrachial Plexus Neuritis: etiology
000266790 650_2 $$2MeSH$$aRetrospective Studies
000266790 650_2 $$2MeSH$$aPolyradiculoneuropathy, Chronic Inflammatory Demyelinating: complications
000266790 650_2 $$2MeSH$$aRare Diseases: complications
000266790 650_2 $$2MeSH$$aHepatitis E: complications
000266790 650_2 $$2MeSH$$aHepatitis E: diagnosis
000266790 650_2 $$2MeSH$$aHepatitis Antibodies
000266790 650_2 $$2MeSH$$aImmunoglobulin M
000266790 650_2 $$2MeSH$$aImmunoglobulin G
000266790 650_7 $$2Other$$aGuillain–Barré syndrome
000266790 650_7 $$2Other$$aGuillain–Barré syndrome
000266790 650_7 $$2Other$$aGuillain–Barré syndrome
000266790 650_7 $$2Other$$aEncephalitis
000266790 650_7 $$2Other$$aGuillain–Barré syndrome
000266790 650_7 $$2Other$$aHepatitis E virus
000266790 650_7 $$2Other$$aNeuralgic amyotrophy
000266790 650_7 $$2Other$$aNeurological manifestation
000266790 650_7 $$2Other$$aPlexus neuritis
000266790 650_7 $$2NLM Chemicals$$aHepatitis Antibodies
000266790 650_7 $$2NLM Chemicals$$aImmunoglobulin M
000266790 650_7 $$2NLM Chemicals$$aImmunoglobulin G
000266790 7001_ $$aStamminger, Thomas$$b1
000266790 7001_ $$aZizer, Eugen$$b2
000266790 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b3$$udzne
000266790 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b4$$eLast author$$udzne
000266790 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-023-11985-8$$gVol. 271, no. 1, p. 386 - 394$$n1$$p386 - 394$$tJournal of neurology$$v271$$x0367-004X$$y2024
000266790 8564_ $$uhttps://pub.dzne.de/record/266790/files/DZNE-2024-00048.pdf$$yOpenAccess
000266790 8564_ $$uhttps://pub.dzne.de/record/266790/files/DZNE-2024-00048.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000266790 909CO $$ooai:pub.dzne.de:266790$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000266790 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002007$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000266790 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000266790 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000266790 9141_ $$y2024
000266790 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000266790 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000266790 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000266790 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000266790 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2023-10-21
000266790 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center Ulm$$lClinical Study Center Ulm$$x0
000266790 980__ $$ajournal
000266790 980__ $$aVDB
000266790 980__ $$aUNRESTRICTED
000266790 980__ $$aI:(DE-2719)5000077
000266790 9801_ $$aFullTexts